Mehmet Oz, M.D., says he will divest from insurance, provider and drugmakers if he earns confirmation from the Senate to run ...

Dr. Mehmet Oz has pledged to eliminate his conflicts of interest before he would helm the Centers for Medicare and Medicaid ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...